Intervention

icotinib

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 6 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials6

Recruiting0

Common conditions3

Lead sponsors shown3

Clinical trials

6 shown

First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR MutationNCT02883543 · 2016-06-01

UNKNOWN

High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon MutationNCT02404675 · 2015-04-01

UNKNOWN

Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung CancerNCT02272127 · 2014-07-01

UNKNOWN

Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic InsufficiencyNCT02062515 · 2014-02-01

UNKNOWN

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR MutationNCT01516983 · 2011-12-01

COMPLETED

Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With ChemotherapyNCT02486354 · 2010-03-01

COMPLETED

Common conditions

Non-small Cell Lung Cancer4 NSCLC2 Brain Metastases1

Leading sponsors

Betta Pharmaceuticals Co., Ltd. 4 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 1 Nanfang Hospital, Southern Medical University 1

Trial status mix

UNKNOWN4

COMPLETED2

Phase mix

PHASE23

PHASE32

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.